InVivoMAb anti-WNV E protein DI-DII

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.

Structural Basis of Zika Virus-Specific Antibody Protection.

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases.

A fusion-loop antibody enhances the infectious properties of immature flavivirus particles.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. Dowd KA et al., 2011 Jun, PLoS Pathog

Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. Oliphant T et al., 2006 Dec, J Virol